Minocycline safety and tolerability in Huntington disease. Academic Article

abstract

• Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.

authors

• Zhao, Hongwei

published proceedings

• Neurology

author list (cited authors)

• Huntington Study Group.

citation count

• 72

publication date

• August 2004

publisher

• Wolters Kluwer  Publisher

published in

• Neurology  Journal

keywords

• Adult
• Apoptosis
• Caspase 3
• Caspase Inhibitors
• Cysteine Proteinase Inhibitors
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Gastrointestinal Diseases
• Humans
• Huntington Disease
• Male
• Middle Aged
• Minocycline
• Patient Dropouts
• Treatment Failure
• Treatment Outcome

PubMed Central ID

• 15304592

Digital Object Identifier (DOI)

• 10.1212/01.wnl.0000133403.30559.ff

start page

• 547

end page

• 549

volume

• 63

issue

• 3

URL

• http://dx.doi.org/10.1212/01.wnl.0000133403.30559.ff